Our PAL-GHK Peptide is designed to meet the industrial criteria and the needs of researchers.Before launching our products, we test them through an independent laboratory to check their purity and ingredients
As researchers continue to explore the compound's full therapeutic capabilities, the list of its potential applications continues to grow
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, currently in clinical development for obesity and type 2 diabetes
It shows higher molecular stability and may target apoptotic cells more effectively
These double-blind, placebo-controlled trials consistently demonstrated that GLP-1 therapy far outperforms traditional weight-loss interventions
Seguridad y efectos secundarios: En dosis altas (superiores a 3-4 g/da) puede causar nuseas, calambres abdominales, diarrea o un olor corporal a pescado